BiotechTube

Intravenous Immune Globulin (IVIG)

Phase 1UNKNOWN
0 watching 0 views this week💤 Quiet
30
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Spinocerebellar Ataxias

Conditions

Spinocerebellar Ataxias

Trial Timeline

Apr 1, 2015 → —

NCT ID
NCT02287064

About Intravenous Immune Globulin (IVIG)

Intravenous Immune Globulin (IVIG) is a phase 1 stage product being developed by Baxter for Spinocerebellar Ataxias. The current trial status is unknown. This product is registered under clinical trial identifier NCT02287064. Target conditions include Spinocerebellar Ataxias.

Hype Score Breakdown

Clinical
10
Activity
5
Company
7
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT02287064Phase 1UNKNOWN

Competing Products

15 competing products in Spinocerebellar Ataxias

See all competitors
ProductCompanyStageHype Score
KPS-0373, High dose + KPS-0373, Low doseKissei PharmaceuticalPhase 3
76
KPS-0373, High dose + KPS-0373, Low dose + PlaceboKissei PharmaceuticalPhase 3
76
KPS-0373, High dose + KPS-0373, Low doseKissei PharmaceuticalPhase 3
76
KPS-0373 + PlaceboKissei PharmaceuticalPhase 3
76
KPS-0373 + PlaceboKissei PharmaceuticalPhase 2
51
KPS-0373 + PlaceboKissei PharmaceuticalPhase 3
76
KPS-0373Kissei PharmaceuticalPhase 2
51
KPS-0373, High dose + KPS-0373, Low doseKissei PharmaceuticalPhase 3
76
varenicline + placeboPfizerPhase 2
51
BIIB132 + BIIB132-Matching PlaceboBiogenPhase 1
30
IVIGBaxterPhase 2
49
ARO-ATXN2 Injection + PlaceboArrowhead PharmaceuticalsPhase 1
30
Troriluzole + Placebo + TroriluzoleBiohavenPhase 2/3
60
BHV-4157BiohavenPre-clinical
18
troriluzole + PlaceboBiohavenPhase 3
72

Other Products from Baxter

FLOSEAL Hemostatic Matrix + Standard of careApproved
82
Esmolol + MetoprololApproved
82
Fibrin Sealant (Tisseel) used in the Experimental Arm.Approved
82
Sevoflurane + propofol + remifentanilApproved
82
Physioneal + Dianeal + Extraneal + NutrinealApproved
82